Recognizing and Addressing the Public's Knowledge Gaps Concerning Aducanumab and Alzheimer Disease

JAMA Netw Open. 2022 Feb 1;5(2):e2148361. doi: 10.1001/jamanetworkopen.2021.48361.
No abstract available

Publication types

  • Comment

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Humans
  • Knowledge
  • Public Opinion

Substances

  • Antibodies, Monoclonal, Humanized
  • aducanumab